CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Vanda Pharmaceuticals Inc. (VNDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Vanda Pharmaceuticals Inc. (VNDA)

Pharmaceutical Preparations · market cap $307M · as of 2026-11-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
PDUFA
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Vanda Pharmaceuticals (VNDA) is a ~$246M market-cap pharmaceutical company (~60.5M shares at ~$4.07) with an existing revenue base of $216M in 2025 and a broad late-stage pipeline spanning CNS, sleep/circadian, GI and dermatology programs. Its listed lead asset is imsidolimab, with an estimated PDUFA date of 2026-12-15 for Acne Vulgaris. That event lands against a thin balance sheet: $61.9M of cash and an estimated 6.5 months of runway after a $220M net loss in 2025.
The catalyst path
  • 2026-12-15 (est.)PDUFA · Imsidolimabimp 8/10
  • 2027-03-15 (est.)Phase 2 · VCA-894Aimp 7/10
  • 2027-09-30 (est.)Phase 3 · Tradipitantimp 9/10
  • 2027-11-15 (est.)Phase 3 · iloperidoneimp 9/10
  • 2027-11-15 (est.)Phase 3 · Tasimelteon Oral Suspensionimp 9/10
Pipeline
AssetPhaseIndication
Tasimelteon Oral SuspensionPhase 3Insomnia Disorder
PonesimodPhase 3Moderate-to-severe Chronic Plaque Psoriasis
ImsidolimabPhase 3Acne Vulgaris
Trichostatin APhase 2Onychomycosis of Toenail
TradipitantPhase 3Motion Sickness
VSF-173Phase 2Excessive Somnolence
Tasimelteon Oral Capsule, Tasimelteon Liquid SuspensionPhase 3Autism Spectrum Disorder
ZiprasidonePhase 3Schizophrenia
VLY-686 (Tradipitant)Phase 2Gastroparesis
TasimelteonPhase 3Sleep Wake Disorders
MilsaperidonePhase 3Major Depressive Disorder (MDD)
VCA-894APhase 2Charcot Marie Tooth Disease (CMT)
iloperidonePhase 3Schizophrenia
Open Label TradipitantPhase 3Idiopathic Gastroparesis
VLY-686Phase 2Treatment-resistant Pruritus Associated With Atopic Dermatitis
Imsidolimab high dosePhase 3Generalized Pustular Psoriasis
VQW-765Phase 3Performance Anxiety
VEC-162Phase 3Circadian Rhythm Sleep Disorders
VSJ-110Phase 2Dry Eye
Oral iloperidonePhase 2Schizophrenia
Price & technical context
3-month
-28.7%
6-month
-36.2%
12-month
-10.6%
52-wk range
$3.59–$9.56
vs 50-day MA
-13.1%
vs 200-day MA
-35.4%
Realized vol
76.7%
Max drawdown
-62.4%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for VNDA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.